Paper Details

  1. Home
  2. Paper Details

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.

Author: , BaughBryan, BrownKimberley, El GhaziMohsine, HuhnGregory D, JezorwskiJohn, LathouwersErkki, MussiniCristina, SpinnerChristoph D, Van LanduytErika, WilkinAimee

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) was effective in treatment-naïve and treatment-experienced, virologically-suppressed adults, regardless of demographic or clinical characteristics. The regimen demonstrated a high barrier to resistance and bone/renal safety benefits.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). OBJECTIVE: To describe a Week 96 pre-planned subgroup...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/25787489.2020.1844520

データ提供：米国国立医学図書館（NLM）

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF): A Single-Tablet Regimen for HIV

The treatment of HIV continues to evolve, with researchers constantly seeking more effective and tolerable regimens. This study investigates the efficacy and safety of a once-daily single-tablet regimen, D/C/F/TAF, in both treatment-naïve and treatment-experienced adults living with HIV-1. The study employed a robust design, utilizing a randomized controlled trial to compare D/C/F/TAF to standard treatments and assess its impact on viral suppression and overall health.

A New Oasis in the Desert of HIV Treatment

The results of this study are encouraging, demonstrating high virologic response rates with D/C/F/TAF, indicating its effectiveness in suppressing HIV-1 replication. Notably, the researchers found no evidence of resistance to the drug's components, highlighting its potential for long-term efficacy. D/C/F/TAF also displayed a favorable safety profile, with low rates of serious adverse events and minimal impact on kidney function. This single-tablet regimen is a game-changer for HIV treatment, offering convenience, efficacy, and a favorable safety profile.

Navigating the Desert of HIV Treatment: A New Path Forward

This study illuminates a promising path forward in the battle against HIV. The development of a convenient, effective, and safe single-tablet regimen is a significant advancement in the treatment landscape. It brings hope to individuals living with HIV, offering a more manageable and potentially life-changing option. This research is a testament to the ongoing dedication of researchers to find new and innovative solutions to combat this complex disease.

Dr.Camel's Conclusion

In the expansive desert of HIV treatment, D/C/F/TAF emerges as a refreshing oasis, offering a convenient and effective solution. This research serves as a reminder that the search for better treatments is a constant journey, and we are constantly uncovering new and innovative ways to combat this formidable foe.

Date :
  1. Date Completed 2022-02-25
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

33528318

DOI: Digital Object Identifier

10.1080/25787489.2020.1844520

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.